{"id":"NCT01426373","sponsor":"Kythera Biopharmaceuticals","briefTitle":"Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area","officialTitle":"Multicenter, Open-label Study of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2011-08-31","resultsPosted":"2016-01-14","lastUpdate":"2016-01-14"},"enrollment":165,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Moderate or Severe Submental Fullness"],"interventions":[{"type":"DRUG","name":"Deoxycholic acid injection","otherNames":["ATX-101","Kybella"]}],"arms":[{"label":"Deoxycholic Acid 2 mg/cm²","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Up to 12 months after last treatment (maximum of 18 months from first treatment)","effectByArm":[{"arm":"Deoxycholic Acid 2 mg/cm²","deltaMin":160,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["31524342"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":165},"commonTop":["Injection site hematoma","Injection site anesthesia","Injection site pain","Injection site edema","Injection site erythema"]}}